What Is Reviva Pharmaceuticals Holdings (RVPH) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Reviva Pharmaceuticals Holdings is potentially undervalued at its current price of $0.58. Based on our 13-model framework, Reviva Pharmaceuticals Holdings's intrinsic value is estimated at a composite fair value of $1.41 — representing +142.4% implied upside — with 5 out of 6 active models confirming this thesis. Model dispersion is worth noting: Sentiment SOTP targets $2.46 (+323.3%), versus ML-RIV at $0.03 (-94.5%). This +417.8% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About RVPH?
6 of 13 models are currently active for RVPH. Of these, 5 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates RVPH's intrinsic value at $1.09, implying +88.2% upside from the current price. See which stocks rank higher →
How Does RVPH Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, RVPH ranks #310 by Quality of Company score. CirclFi's QOC score of 4.2/10 evaluates 32 fundamental signals. A score of 4.2 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Reviva Pharmaceuticals Holdings's positioning within the Pharmaceutical Preparations segment means that FDA approval probability plays an outsized role in fundamental analysis. The sector's unique characteristics — including orphan drug designation — shape both the opportunity set and risk profile.
Is RVPH a Value Trap?
CirclFi's Value Trap algorithm assigns RVPH a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
6 of 13 models are active for Reviva Pharmaceuticals Holdings. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Reviva Pharmaceuticals Holdings earns a quality score of 4.2/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +417.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every RVPH valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across RVPH's 6 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad